At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin
In Brief
A Phase 3 clinical trial evaluating Saxagliptin, Dapagliflozin, and 2 other interventions for Type 2 Diabetes. Completed, enrolled 315 participants across 83 sites in 9 countries.
Detailed Summary
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
Study Details
Timeline
Interventions
Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
Tablets, Oral, 0 mg, Once daily, Up to 52 weeks